Skip to main content
Erschienen in: Nutrition Journal 1/2016

Open Access 01.12.2015 | Erratum

Erratum to: the effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial

verfasst von: Michael N. Pakdaman, Jay K. Udani, Jhanna Pamela Molina, Michael Shahani

Erschienen in: Nutrition Journal | Ausgabe 1/2016

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found under doi:10.​1186/​s12937-016-0172-y.

Erratum

This erratum is in response to comments made to our recently published study “The Effects of the DDS-1 Strain of Lactobacillus on Symptomatic Relief for Lactose Intolerance - A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial” [1].
The Frese et. al. study [2] compares autochthonous strains of Lactobacillus to DDS-1, an allochthonous strain. This is a significant aspect of their study, as an allochthonous strain would generally not be expected to establish in higher levels compared with a strain naturally found in the human gastrointestinal tract. The comment “the DDS-1 strain of L. acidophilus to be superior to other strains of lactobacillus in the ability to establish in the human gastrointestinal (GI) tract [2]” refers to its ability to colonize the GI tract compared with other allochthonous strains, which in other studies have not been shown to establish well in the human gastrointestinal tract. While it is true what the reader states that “authors found that only in a small number of subjects did the strain survive gastric passage, and the strain did so in lower numbers and in fewer subjects than the other Lactobacillus species tested” - this is expected as an allochthonous strain (eg DDS-1) would not be expected to demonstrate superior colonization compared with a strain naturally found in the human gastrointestinal tract (e.g. Lactobacillus reuteri and mucosae).
With regard to the statement “However, it has been previously reported that the DDS-1 strain does successfully establish in the human gastrointestinal tract [2].” This statement is true. It is important to note that nowhere in the article do we suggest that someone consume DDS-1 for 8 days, then discontinue the product altogether and expected for it to work. The purpose of our reference to that study is that DDS-1 does successfully establish in the gastrointestinal tract. We made no comments on for how long or if it is superior than strains naturally occurring in the human body.
With regard to the reader’s comment “It is clear from this previous work that the allochthonous DDS-1 is a poor choice with respect to gastric transit, establishment of Lactobacillus populations in the gastrointestinal tract, and in comparison to other Lactobacillus species,” we disagree. While we agree that it is not superior to strains naturally found in the human gastrointestinal tract (eg Lactobacillus reuteri and mucosae), it is not expected to be so. The purpose for reference to the Frese et al. article was to demonstrate that the DDS-1 strain of L. Acidophilus in fact does colonize, suggesting that symptom improvement during consumption can be potentially linked to this colonization.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Pakdaman MN, Udani JK, Molina JP, Shahani M. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr J. 2016;15:56.CrossRefPubMedPubMedCentral Pakdaman MN, Udani JK, Molina JP, Shahani M. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr J. 2016;15:56.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Frese SA, Hutkins RW, Walter J. Comparison of the colonization ability of autochthonous and allochthonous strains of lactobacilli in the human gastrointestinal tract. Adv Microb. 2012;2:399.CrossRef Frese SA, Hutkins RW, Walter J. Comparison of the colonization ability of autochthonous and allochthonous strains of lactobacilli in the human gastrointestinal tract. Adv Microb. 2012;2:399.CrossRef
Metadaten
Titel
Erratum to: the effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial
verfasst von
Michael N. Pakdaman
Jay K. Udani
Jhanna Pamela Molina
Michael Shahani
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Nutrition Journal / Ausgabe 1/2016
Elektronische ISSN: 1475-2891
DOI
https://doi.org/10.1186/s12937-016-0199-0

Weitere Artikel der Ausgabe 1/2016

Nutrition Journal 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.